Evidence map›Paper›PMID 41240237›Full record

ReviewMolecular biology reports2025

Genetic factors in the risk assessment of preeclampsia: a review of recent findings.

Aslihan Esra Bildirici, Mete Hakan Karalök, Ayşegül Akbay

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aslihan Esra BildiriciFaculty of Medicine, Department of Medical Genetics, Yuksek Ihtisas University, 06530, Ankara, Turkey. aslihanesrabicer@yiu.edu.tr.
Mete Hakan KaralökDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, USA.
Ayşegül AkbayFaculty of Medicine, Department of Medical Biochemistry, Yuksek Ihtisas University, 06530, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preeclampsia, characterized by high blood pressure, proteinuria and organ dysfunction in severe cases is a hypertensive disorder that occurs during pregnancy. There is strong evidence that this disease, whose etiology remains unclear, is a complex condition involving programming changes at the levels of DNA, epigenetics, transcriptomics, proteins, and metabolites. Clinically, understanding how each of these elements influences the disease state can provide valuable insights into treatment and prevention strategies. Despite significant advancements in the diagnosis and management of preeclampsia, the syndrome remains a leading cause of maternal mortality, lifelong morbidity, and adverse fetal outcomes. Recent genetic studies offer new insights into the underlying mechanisms of preeclampsia and opens up exciting possibilities for early risk assessment and personalized medical interventions. This article reviews the latest findings on genetic susceptibility to preeclampsia and explores the integration of genetic data into clinical practice.

Indexed as

Genetic Predisposition to DiseasePre-EclampsiaEpigenesis, GeneticFemaleHumansPregnancyRisk AssessmentRisk FactorsEpigeneticFetal genomeGeneticMachine learningMaternal genomePolygenic risk scorePreeclampsia

Identifiers

PMID41240237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.